Home › Funds › Affinity Asset Advisors, LLC › XENE

Affinity Asset Advisors, LLC position in XENE

XENON PHARMACEUTICALS INC · Health Care

Affinity Asset Advisors, LLC reported holding 1,900,374 shares of XENE (XENON PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$70.7M, representing 3.29% of its reported portfolio and ranking #7 among its reported holdings. Affinity Asset Advisors, LLC has disclosed XENE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.90M sh
Reported value held$70.67M
Portfolio Weight3.29%
First reportedQ3 2023
Last changeAdd
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Affinity Asset Advisors, LLC's XENE position evolved

Affinity Asset Advisors, LLC first disclosed a stake in XENE in Q3 2023 at 300,438 shares (US$10.3M). The position peaked in Q1 2026 at 1,675,000 shares, worth US$97.4M. Across 13 filings, Affinity Asset Advisors, LLC increased the stake 9 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,900,374 shares valued at US$70.7M — an increase of 305,374 shares quarter over quarter.. Notable position changes include a 53% increase in Q4 2023 (shares fell 7% over the following quarter), a 82% increase in Q1 2024 (shares fell 9% over the following quarter), a 34% increase in Q1 2026 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 300.44K $10.26M New
Q4 2023 460.00K $21.19M Add
Q1 2024 837.39K $36.05M Add
Q2 2024 994.23K $38.76M Add
Q3 2024 1.14M $45.04M Add
Q4 2024 1.16M $45.52M Add
Q1 2025 1.33M $44.56M Add
Q2 2025 1.10M $34.43M Reduce
Q3 2025 1.40M $56.21M Add
Q4 2025 1.25M $56.02M Reduce
Q1 2026 1.68M $97.40M Add
Q2 2026 1.59M $96.27M Reduce
Q3 2026 1.90M $70.67M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XENE and 13F data

XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$266.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XENE

All XENE fund holders →

FAQ

How long has Affinity Asset Advisors, LLC held XENE?

Affinity Asset Advisors, LLC has disclosed XENE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Affinity Asset Advisors, LLC's current position in XENE?

As of Q3 2026, Affinity Asset Advisors, LLC holds 1.90M shares of XENE (XENON PHARMACEUTICALS INC), valued at $70.67M, representing 3.29% of its reported portfolio and ranking #7.

Has Affinity Asset Advisors, LLC been buying or selling XENE?

In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC increased its position in XENE. The position peaked in Q1 2026 at 1.68M shares.

Which other funds hold XENE?

Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DRIEHAUS CAPITAL MANAGEMENT LLC, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.